| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(5 years from now) | |
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940146 | ARDELYX INC | NHE3-binding compounds and methods for inhibiting phosphate transport |
Apr, 2034
(9 years from now) | |
| US10272079 | ARDELYX INC | NHE3-binding compounds and methods for inhibiting phosphate transport |
Apr, 2034
(9 years from now) | |
Xphozah is owned by Ardelyx Inc.
Xphozah contains Tenapanor Hydrochloride.
Xphozah has a total of 4 drug patents out of which 0 drug patents have expired.
Xphozah was authorised for market use on 17 October, 2023.
Xphozah is available in tablet;oral dosage forms.
Xphozah can be used as treatment of hyperphosphatemia.
Drug patent challenges can be filed against Xphozah from 13 September, 2023.
The generics of Xphozah are possible to be released after 10 April, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of hyperphosphatemia
Dosage: TABLET;ORAL
More Information on Dosage
XPHOZAH family patents
